logo
  

Karyopharm Therapeutics Inc. Q1 Loss increases, but beats estimates

Karyopharm Therapeutics Inc. (KPTI) revealed Loss for its first quarter that increased from the same period last year but beat the Street estimates.

The company's earnings came in at -$37.36 million, or -$0.32 per share. This compares with -$34.13 million, or -$0.30 per share, in last year's first quarter.

Analysts on average had expected the company to earn -$0.33 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 14.4% to $33.13 million from $38.70 million last year.

Karyopharm Therapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$37.36 Mln. vs. -$34.13 Mln. last year.
-EPS (Q1): -$0.32 vs. -$0.30 last year.
-Revenue (Q1): $33.13 Mln vs. $38.70 Mln last year.

-Guidance:
Full year revenue guidance: $140 Mln-$160 Mln

For comments and feedback contact: editorial@rttnews.com

The highlight this week was the latest set of first quarter economic growth figures from the U.S. Find out why the data damped the market sentiment. Other main releases from the U.S. included those on consumer confidence and jobless claims. In Europe, German inflation figures caught everyone's attention. Learn why it added to expectations of rate staying “higher for longer”. Asia's economics scene this week was dominated by the release of PMI survey figures from China.

View More Videos
RELATED NEWS
Follow RTT